Menopausal hormone therapy and non-gynecological cancer (neoplasms of the digestive organs)

• Oksana V. Yakushevskaya
• Yureneva S.V.
• Protasova Anna E.
• Khabas G.N.
• Ashrafyan Lev A.

Abstract

The aim of the study was to conduct system analysis of available research results on the possibility of menopausal hormone therapy (MHT) usage in patients who successfully completed treatment of malignant tumors of digestive organs.

Material and methods. The review includes data from foreign articles that were found in Pubmed and Medline databases and domestic articles that were posted on elibrary.ru over the past 20 years.

Results. The attained results allow to extend MHT prescription range in patients with malignant tumors of digestive organs in past medical history. This study is the latest in series of few efforts of clinicians to justify MHT usage as one of for still imperfect oncology patient rehabilitation methods.

Conclusion. Patients who have successfully completed treatment of malignant tumors of digestive organs require the creation of special conditions of rehabilitation in order to preserve health and quality of life, and must be under close medical supervision. Adequately supported MHT prescription for the patients will allow to avoid complications associated with estrogen deficiency after surgical, radiological therapeutic interventions with systemic (cytostatic) treatment or without it

Keywords:hormone replacement therapy, systemic (cytostatic) therapy, esophageal carcinoma, esophageal squamous cell carcinoma, esophageal adenocarcinoma, stomach cancer, gastric adenocarcinoma, climacteric syndrome, medical rehabilitation

References

1. Nie X., Xie R., Tuo B. Effects of Estrogen on the Gastrointestinal Tract. Dig Dis Sci. 2018; 63 (3): 583-96. doi: 10.1007/s10620-018-4939-1. Epub 2018 Jan 31.

2. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow, 2018. (in Russian)

3. Hogan A.M., Collins D., Baird A.W., Winter D.C. Estrogen and gastrointestinal malignancy. Mol Cell Endocrinol. 2009; 307 (1-2): 19-24.

4. Green J., Roddam A., Pirie K., Kirichek O., et al.; Million Women Study Collaborators. Reproductive factors and risk of oesophageal and gastric cancer in the Million Women Study cohort. Br J Cancer. 2012; 106 (1): 210-6. doi: 10.1038/bjc.2011.525. Epub 2011 Nov 29.

5. Zhu Y., Yue D., Yuan B., Zhu L., et al. Reproductive factors are associated with oesophageal ancer risk: Results from a meta-analysis of observational studies. Eur J Cancer Prev. 2017; 26: 1-9. doi: 10.1097/CEJ.0000000000000234.

6. Abnet C.C., Arnold M., Wei W.Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018; 154 (2): 360-73. doi: 10.1053/j.gastro.2017.08.023. Epub 2017 Aug 18.

7. Zheng D., Williams C., Vold J.A., Nguyen J.H. et al. Regulation of sex hormone receptors in sexual dimorphism of human cancers. Cancer Lett. 2018; 438: 24-31. doi: 10.1016/j.canlet.2018.09.001. Epub 2018 Sep 14.

8. Hyland P., Freedman N.D., Hu N. Genetic variants in sex hormone metabolic pathway genes and risk of esophageal squamous cell carcinoma. Carcinogenesis. 2013; 34 (5) 1062-8. doi: 10.1093/carcin/bgt030. Epub 2013 Jan 28.

9. Fernandez E., Gallus S., Bosetti C., Franceschi S., et al. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer. 2003; 105: 408-12.

10. Lindblad M., Garcia Rodriguez L.A., Chandanos E., Lagergren J. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer. 2006; 94 (1): 136-41.

11. Cronin-Fenton D.P., Murray L.J., Whiteman D.C. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer. 2010; 46: 2067-76.

12. Freedman N.D., Lacey J.V. Jr, Hollenbeck A.R., Leitzmann M.F., et al. The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. Cancer. 2010; 116: 1572-81.

13. Hui Yu. Hormonal and reproductive factors and risk of esophageal cancer in Chinese postmenopausal women: a case-control study. Asian Pac. J. Cancer Prev. 2011. Vol. 12. P. 1953-1956.

14. Menon S., Nightingale P., Trudgill N. Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer? United European Gastroenterol J. 2014; 2 (5): 374382.

15. Lagergren K. Hormone replacement therapy and oral contraceptives and risk of oesophageal adenocarcinoma: a systematic review and meta-analysis. Int J Cancer. 2014; 135: 2183-190.

16. Wang B.J. Hormonal and reproductive factors and risk of esophageal cancer in women: a meta-analysis. Dis Esophagus. 2016; 29: 44854.

17. Brusselaers N., Maret-Ouda J., Konings P. Menopausal hormone therapy and the risk of esophageal and gastric cancer. Int J Cancer. 2017; 140: 1693-9.

18. Zhu Y., Yue D., Yuan B., Zhu L., et al. Reproductive factors are associated with oesophageal cancer risk: results from a meta-analysis of observational studies. Eur. J. Cancer Prev. 2017; 26: 1-9.

19. Matsuyama S., Ohkura Y., Eguchi H., Kobayashi Y., et al. Estrogens receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol. 2002; 128 (6): 319-24.

20. Kim S.M. Protective effects of female reproductive factors on Lauren intestinal-type gastric adenocarcinoma. Yonsei Med J. 2018; 59 (1): 28-34.

21. Wu C.W., Lui W.Y., P'eng F.K., Chi C.W. Hormonal therapy for stomach cancer. Med Hypotheses. 1992; 39 (2): 137-9.

22. Ikeguchi M., Fukuda K., Oka S., Yamaguchi K., et al. Clinicopatho-logical significance of cathepsin D expression in gastric adenocarcinoma. Oncology. 2001; 61 (1): 71-8.

23. Kim H.W., Kim J.H., Lim B.J. Sex disparity in gastric cancer: female sex is a poor prognostic factor for advanced gastric cancer. Ann Surg Oncol. 2016; 23 (13): 4344-51.

24. La Vecchia C., D'Avanzo B., Franceschi S., Negri E. et al. Menstrual and reproductive factors and gastric-cancer risk in women. Int J Cancer. 1994; 59: 761-4.

25. Chandans E. Estrogen in the Development of Esophageal and Gastric Adenocarcinoma. Stockholm: Karolinska Institutet, 2007.

26. Duell E., Travier N., Lujan-Barroso L. Menstrual and reproductive factors, exogenous hormone use, and gastric cancer risk in a cohort of women from the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol. 2010; 172: 1384-93.

27. Camargo M., Goto Y., Zabaleta J., Morgan D.R., et al. Sex hormones, hormonal interventions and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012; 21 (1): 20-38.

28. Lope V., Fernandez de Larrea N., Perez-Gomez B. Menstrual and reproductive factors and risk of gastric and colorectal cancer in Spain. PLoS One. 2016; 11. doi: 10.1371/journal.pone.0164620. (date of access October 24, 2016)

29. Prentice R.L., Pettinger M., Beresford S.A.A., Wactawski-Wende J., et al. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev. 2009; 18 (5): 1531-7.

30. Marjoribanks J., Farquhar C., Roberts H., Lethaby A., et al. Long-termhormone therapy for perimenopausal and postmenopausal women (review)/ Cochrane Database Syst Rev. 2017. Vol. 1. CD004143.

31. Genazzani A.R. Hormone Replacement Therapy and Cancer: The Current Status of Research and Practice. CRC Press, 2002. 296 p.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)